Vasopressin is indicated for the management of vasodilatory shock, especially septic shock, when blood pressure remains low despite adequate fluid resuscitation and catecholamine therapy. Its key advantage is a non-adrenergic mechanism of action via V1 receptors, which restores vascular tone even in patients who are refractory to conventional vasopressors. This makes it highly valuable in ICU settings where rapid stabilization of hemodynamics is critical. Vasopressin also reduces the required dose of catecholamines such as norepinephrine, helping decrease the risk of arrhythmias and other adverse effects. In addition, it supports organ perfusion by improving systemic vascular resistance in a controlled manner. Its predictable effect and complementary role in shock management make it an essential component of modern critical care protocols.